Photocure’s Photodynamic Therapy Shows Promise In Cervical Dysplasia
This article was originally published in The Pink Sheet Daily
Photocure's combination of intravaginal photosensitizer and a light-emitting device has shown therapeutic benefit in cervical dysplasia, so the small Norwegian company now seeks a women's health care specialist to help take it into Phase III.
You may also be interested in...
Indivior aims to cut costs by restructuring its US commercial operations and reducing discretionary spending, in order to improve flexibility in the face of the COVID-19 pandemic and to invest in R&D.
The rollercoaster ride continues for Novartis’s gene therapy Zolgensma, with the company committing to providing further clinical data on an intrathecal formulation for older spinal muscular atrophy patients.
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.